JP2004537252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537252A5 JP2004537252A5 JP2001537498A JP2001537498A JP2004537252A5 JP 2004537252 A5 JP2004537252 A5 JP 2004537252A5 JP 2001537498 A JP2001537498 A JP 2001537498A JP 2001537498 A JP2001537498 A JP 2001537498A JP 2004537252 A5 JP2004537252 A5 JP 2004537252A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cell
- isolated
- cells
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 9
- 210000001744 T-Lymphocytes Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 102000037240 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Images
Description
【特許請求の範囲】
【請求項１】
配列番号113の断片からなる単離されたポリペプチドであって、該断片が、配列番号539又は540に記載されたＴ細胞エピトープ配列を少なくとも含む、上記ポリペプチド。
【請求項２】
配列番号539または540に記載のアミノ酸配列からなる、単離Ｔ細胞エピトープ。
【請求項３】
発現制御配列に機能的に連結された、請求項１に記載のポリペプチドをコードするポリヌクレオチドを含む、発現ベクター。
【請求項４】
請求項３に記載の発現ベクターにより形質転換又はトランスフェクションされた、宿主細胞。
【請求項５】
請求項１に記載のポリペプチドを含む、融合タンパク質。
【請求項６】
前立腺腫瘍タンパク質に特異的な免疫応答を刺激するための医薬の製造における、請求項１に記載のポリペプチド又は請求項５に記載の融合タンパク質の使用。
【請求項７】
Ｔ細胞の刺激及び／又は増殖を可能にするために十分な条件下及び時間にわたり、Ｔ細胞を、以下の：
（ｉ）請求項１に記載のポリペプチド；
（iii）（i）のポリペプチドをコードするポリヌクレオチド；及び／又は
（iv）（i）のポリペプチドを発現する抗原提示細胞、
のうち１以上と接触させることを含む、前立腺腫瘍タンパク質特異的Ｔ細胞を刺激し及び／又は増殖させる方法。
【請求項８】
請求項７に記載の方法に従って調製されたＴ細胞を含む、単離Ｔ細胞集団。
【請求項９】
生理学的に許容される担体及び免疫刺激剤から成る群より選択される第１成分、並びに、以下：
（a）請求項１に記載のポリペプチド；
（b）請求項２に記載の単離Ｔ細胞エピトープ；
（c）請求項５に記載の融合タンパク質；
（d）請求項８に記載のＴ細胞集団；及び
（e）請求項１に記載のポリペプチドを発現する抗原提示細胞、
から成る群より選択される第２成分を含む、組成物。
【請求項１０】
免疫応答を刺激するための医薬の製造における、請求項９に記載の組成物の使用。
【請求項１１】
癌の治療のための医薬の製造における、請求項９に記載の組成物の使用。
【請求項１２】
（a）患者から単離されたＣＤ４＋及び／又はＣＤ８＋Ｔ細胞を、以下：
（i）請求項１に記載のポリペプチド；
（ii）請求項２に記載の単離Ｔ細胞エピトープ；
（iii）請求項１に記載のポリペプチドを発現する抗原提示細胞；及び
（iv）請求項５に記載の融合タンパク質、
から成る群より選択される少なくとも１つの成分とともに、Ｔ細胞が増殖するようにインキュベートすること
により増殖させた、癌発達を阻害するための医薬の製造における使用のための、単離Ｔ細胞。
[Claims]
[Claim 1]
An isolated polypeptide comprising a fragment of SEQ ID NO: 113, wherein said fragment comprises at least the T cell epitope sequence set forth in SEQ ID NO: 539 or 540.
[Claim 2]
An isolated T cell epitope consisting of the amino acid sequence set forth in SEQ ID NO: 539 or 540.
[Claim 3]
An expression vector comprising a polynucleotide encoding a polypeptide of
[Claim 4]
A host cell transformed or transfected with the expression vector according to
[Claim 5]
A fusion protein comprising the polypeptide of
[Claim 6]
Use of the polypeptide of
[Claim 7]
Under conditions and for a time sufficient to allow stimulation and / or proliferation of T cells, the T cells are:
(I) the polypeptide of
(Iii) a polynucleotide encoding the polypeptide of (i); and / or (iv) an antigen-presenting cell that expresses the polypeptide of (i),
A method of stimulating and / or proliferating prostate tumor protein-specific T cells comprising contacting with one or more of the above.
[Claim 8]
8. An isolated T cell population comprising T cells prepared according to the method of
[Claim 9]
A first component selected from the group consisting of a physiologically acceptable carrier and an immunostimulant, and the following:
(A) the polypeptide of
(B) the isolated T cell epitope of
(C) the fusion protein according to
(D) the T cell population according to
A composition comprising a second component selected from the group consisting of:
[Claim 10]
Use of the composition according to claim 9 in the manufacture of a medicament for stimulating an immune response.
11. Claims
Use of the composition according to claim 9 in the manufacture of a medicament for the treatment of cancer.
[Claim 12]
(A) CD4 + and / or CD8 + T cells isolated from a patient are:
(I) the polypeptide of
(Ii) the isolated T cell epitope of
(Iii) an antigen-presenting cell that expresses the polypeptide of
An isolated T cell for use in the manufacture of a medicament for inhibiting cancer development, which has been grown by incubating the T cell to proliferate with at least one component selected from the group consisting of:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/439,313 US6329505B1 (en) | 1997-02-25 | 1999-11-12 | Compositions and methods for therapy and diagnosis of prostate cancer |
| US44368699A | 1999-11-18 | 1999-11-18 | |
| PCT/US2000/030904 WO2001034802A2 (en) | 1999-11-12 | 2000-11-09 | Compositions and methods for the therapy and diagnosis of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009017430A Division JP2009142284A (en) | 1999-11-12 | 2009-01-29 | Composition and method for therapy and diagnosis of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537252A JP2004537252A (en) | 2004-12-16 |
| JP2004537252A5 true JP2004537252A5 (en) | 2008-05-22 |
Family
ID=27032000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537498A Pending JP2004537252A (en) | 1999-11-12 | 2000-11-09 | Compositions and methods for treatment and diagnosis of prostate cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1230364A2 (en) |
| JP (1) | JP2004537252A (en) |
| AU (1) | AU1656501A (en) |
| CA (1) | CA2391369A1 (en) |
| WO (1) | WO2001034802A2 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US20030125536A1 (en) * | 1996-01-11 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6620922B1 (en) | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6657056B2 (en) | 1997-02-25 | 2003-12-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6759515B1 (en) | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US6630305B1 (en) | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US6818751B1 (en) | 1997-08-01 | 2004-11-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6894146B1 (en) | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| ATE426018T1 (en) | 1997-04-10 | 2009-04-15 | Stichting Katholieke Univ | PCA3, PCA3 GENES AND METHODS FOR USE THEREOF |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| AU757698C (en) | 1998-06-01 | 2004-04-08 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| ES2260059T3 (en) | 1999-09-29 | 2006-11-01 | Diagnocure Inc. | RNA MESSENGER OF PCA3 IN BENIGN AND MALIGNED PROSTATE FABRICS. |
| US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| DE60033583T2 (en) * | 1999-10-07 | 2007-09-13 | Corixa Corp. CSC, Wilmington | A MYCOBACTERIUM TUBERCULOSIS ENCODING SEQUENCE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS |
| US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
| CZ20022756A3 (en) * | 2000-01-14 | 2003-02-12 | Corixa Corporation | Compositions and methods for treating and diagnosis of prostate cancer |
| CA2403909A1 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20020009455A1 (en) * | 2000-04-27 | 2002-01-24 | Ted Lau | DNA encoding a novel PROST 03 polypeptide |
| ATE442866T1 (en) | 2000-06-20 | 2009-10-15 | Corixa Corp | FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS |
| CA2422642A1 (en) * | 2000-10-03 | 2002-04-11 | Human Genome Sciences, Inc. | Human prostate specific g-protein receptor hpraj70 |
| US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| ES2537074T3 (en) | 2001-09-06 | 2015-06-02 | Agensys, Inc. | Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| PT1511768E (en) * | 2002-06-11 | 2007-07-16 | Glaxo Group Ltd | Immunogenic compositions |
| WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| WO2004070056A2 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| EP1636379A2 (en) * | 2003-06-26 | 2006-03-22 | Exonhit Therapeutics S.A. | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis |
| CA2563735C (en) | 2004-04-22 | 2020-07-14 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| PT2845866T (en) | 2006-10-27 | 2017-08-09 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041289A (en) * | 1987-11-13 | 1991-08-20 | Becton Dickinson And Company | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells |
| NZ331866A (en) * | 1996-03-15 | 2000-05-26 | Corixa Corp | Compounds for immunotherapy and immunodiagnosis of prostate cancer |
| TR199902053T2 (en) * | 1997-02-25 | 2000-04-21 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use. |
| CO4870792A1 (en) * | 1997-02-25 | 1999-12-27 | Corixa Corp | COMPOUNDS AND SET OF DIAGNOSTIC MEANS TO DETECT AND MONITOR THE PROGRESSION OF CANCER OF PROSTATE |
| WO1998050567A1 (en) * | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| WO1999067384A2 (en) * | 1998-06-22 | 1999-12-29 | Incyte Pharmaceuticals, Inc. | Prostate cancer-associated genes |
| TW200532020A (en) * | 1998-07-14 | 2005-10-01 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
| AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
-
2000
- 2000-11-09 WO PCT/US2000/030904 patent/WO2001034802A2/en active Application Filing
- 2000-11-09 JP JP2001537498A patent/JP2004537252A/en active Pending
- 2000-11-09 AU AU16565/01A patent/AU1656501A/en not_active Abandoned
- 2000-11-09 CA CA002391369A patent/CA2391369A1/en not_active Abandoned
- 2000-11-09 EP EP00979155A patent/EP1230364A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537252A5 (en) | ||
| Kiyono et al. | NALT-versus Peyer's-patch-mediated mucosal immunity | |
| AU749544B2 (en) | Tumor antigen peptides originating in cyclophilin B | |
| Fallarino et al. | Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo | |
| ES2373055T3 (en) | ANTIQUE PENCIL OF CANCER REJECTION DERIVED FROM GLIPICAN-3 (GPC3) FOR USE IN PATIENTS POSITIVE TO HLA-A2 AND PHARMACEUTICAL PRODUCT THAT INCLUDES THE ANTIGEN. | |
| EP2626081B1 (en) | Immunogenic control of tumours and tumour cells | |
| JP2021502414A5 (en) | ||
| CN102174479B (en) | Oncolytic virus for targeted treatment of human tumors and application thereof | |
| JP2002505843A5 (en) | ||
| CA2245702A1 (en) | Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same | |
| CA2361009A1 (en) | Her-2/neu fusion proteins | |
| CA2641565A1 (en) | Nel-related proteins type 1 and 2, and polynucleotides encoding them | |
| JP2020502262A5 (en) | ||
| JP2006515749A5 (en) | ||
| IL142905A0 (en) | Functional antagonists of hedgehog activity | |
| JP2001516226A (en) | Compositions and methods for inducing an immune response to tumor-associated antigens | |
| CA2262756A1 (en) | A tumor necrosis factor related ligand | |
| UA79235C2 (en) | Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition | |
| CN109575142B (en) | CD4 helper T cell epitope fusion peptide and vaccine thereof | |
| Colluru et al. | Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses | |
| TW202146435A (en) | Compositions containing a pathogenic antigen and an immune stimulator | |
| NZ333203A (en) | Tumour antigen proteins, genes thereof, and tumour antigen peptides | |
| CA2522994A1 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
| JP2003529608A5 (en) | ||
| Nelson et al. | Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products |